# Paxalisib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/paxalisib

> The next catalyst for paxalisib, sponsored by KAZIA THERAPEUTICS LTD (KZIA), is its topline data readout, early 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for paxalisib?

The next catalyst for paxalisib, sponsored by KAZIA THERAPEUTICS LTD (KZIA), is its topline data readout, early 2027. SEC prospectus (424B): "the anticipated timing of topline data from our Phase 1b trial in advanced triple-negative breast cancer in early 2027 and the expected enrollment of 36 patients in such trial;" [Calendar and source filings](https://sec-api.dev/pdufa/paxalisib)

Source: SEC prospectus (424B), accession 0001213900-26-095303, https://www.sec.gov/Archives/edgar/data/1075880/000121390026095303/ea0303882-424b5_kazia.htm (retrieved 2026-11-12). Last confirmed 2026-08-31. Cite: https://sec-api.dev/pdufa/paxalisib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | paxalisib |
| Codes | SVG103, GDC-0084 |
| Sponsor | KAZIA THERAPEUTICS LTD (KZIA) https://sec-api.dev/companies/kzia/catalysts |
| Indications | newly- diagnosed and recurrent glioblastoma |
| Modality | small_molecule |
| FDA designations | fast track, orphan |

## Timeline

### Jun 2021: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: newly- diagnosed and recurrent glioblastoma.
- First seen 2024-11-15, last confirmed 2024-11-15.
- SEC Form 10-K (accession 0001193125-24-259805): "In June 2021, the company entered into an agreement with Weill Cornell Medicine for an investigator-initiated phase II clinical trial combining paxalisib with ketogenesis in patients with newly- diagnosed and recurrent glioblastoma." https://www.sec.gov/Archives/edgar/data/1075880/000119312524259805/d872361d20f.htm

### June 5, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-06-05, last confirmed 2025-06-11.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-139172): "Kazia recently announced that the first patient has been dosed in the Phase 1b trial evaluating paxalisib in combination with checkpoint inhibitors and chemotherapy in advanced breast cancer, marking a critical step toward clinical translation of these findings." https://www.sec.gov/Archives/edgar/data/1075880/000119312525139172/d116207dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-135383): "Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer" https://www.sec.gov/Archives/edgar/data/1075880/000119312525135383/d832779dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-135383): "KZIA) (Kazia or the Company), an oncology-focused biotechnology company developing innovative therapies for difficult-to-treat cancers, today announced that the first patient has been dosed in a Phase 1b clinical trial sponsored by Kazia." https://www.sec.gov/Archives/edgar/data/1075880/000119312525135383/d832779dex991.htm

### early 2027: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2026-01-27, last confirmed 2026-08-31.
- SEC prospectus (424B) (accession 0001213900-26-095303): "the anticipated timing of topline data from our Phase 1b trial in advanced triple-negative breast cancer in early 2027 and the expected enrollment of 36 patients in such trial;" https://www.sec.gov/Archives/edgar/data/1075880/000121390026095303/ea0303882-424b5_kazia.htm
- SEC prospectus (424B) (accession 0001213900-26-094426): "the anticipated timing of topline data from our Phase 1b trial in advanced triple-negative breast cancer in early 2027 and the expected enrollment of 36 patients in such trial;" https://www.sec.gov/Archives/edgar/data/1075880/000121390026094426/ea0303701-424b5_kazia.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-023379): "Kazia continues to anticipate the targeted enrollment of twelve TNBC pts target by the end of 2026 and topline data readout in early 2027" https://www.sec.gov/Archives/edgar/data/1075880/000119312526023379/d85882dex991.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/paxalisib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Paxalisib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/paxalisib

```bibtex
@misc{secapidev_pdufa_paxalisib_20261116,
  title        = {Paxalisib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/paxalisib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_paxalisib_20261116","title":"Paxalisib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/paxalisib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
